Literature DB >> 14661437

Expression of EphB4 in head and neck squamous cell carcinoma.

Uttam K Sinha1, Ajay Kundra, Pierluigi Scalia, Diane L Smith, Behdad Parsa, Rizwan Masood, Parkash S Gill.   

Abstract

EphB4 is a receptor tyrosine kinase that is expressed on epithelial cells during fetal life. It is also expressed on some venous endothelial cells. We conducted a study of six men with primary squamous cell carcinoma of the head and neck (HNSCC) that had metastasized to the cervical lymph nodes. Our goal was to determine if EphB4 is aberrantly expressed in cases of HNSCC and to determine if there is a qualitative difference between the expression of EphB4 on primary and metastatic tumors and its expression on normal mucosa adjacent to primary tumors. From each patient, we obtained specimens of the primary tumor, the nodal metastasis, and the adjacent normal mucosa, and we performed immunocytochemistry on each. We observed EphB4 expression in all primary and metastatic tumors and no expression in the normal tissue. In each of the six patients, expression was greater in the metastatic tumor than in the primary tumor. We conclude that EphB4 is a novel target in the treatment of HNSCC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14661437

Source DB:  PubMed          Journal:  Ear Nose Throat J        ISSN: 0145-5613            Impact factor:   1.697


  14 in total

1.  Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition.

Authors:  Benjamin D Ferguson; Maria S Tretiakova; Mark W Lingen; Parkash S Gill; Ravi Salgia
Journal:  Growth Factors       Date:  2014-11-13       Impact factor: 2.511

2.  The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth.

Authors:  Nathalie Kertesz; Valery Krasnoperov; Ramachandra Reddy; Lucy Leshanski; S Ram Kumar; Sergey Zozulya; Parkash S Gill
Journal:  Blood       Date:  2005-12-01       Impact factor: 22.113

3.  KSR1 and EPHB4 Regulate Myc and PGC1β To Promote Survival of Human Colon Tumors.

Authors:  Jamie L McCall; Drew Gehring; Beth K Clymer; Kurt W Fisher; Binita Das; David L Kelly; Hyunseok Kim; Michael A White; Robert E Lewis
Journal:  Mol Cell Biol       Date:  2016-08-12       Impact factor: 4.272

Review 4.  EphB4: A promising target for upper aerodigestive malignancies.

Authors:  Ravi Salgia; Prakash Kulkarni; Prakash S Gill
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-01-31       Impact factor: 10.680

5.  The role of EphB4 and IGF-IR expression in breast cancer cells.

Authors:  Gena Huang; Man Li
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

6.  EphB4 regulates the growth and migration of pancreatic cancer cells.

Authors:  Man Li; Jinbo Zhao; Jinjing Qiao; Chen Song; Zuowei Zhao
Journal:  Tumour Biol       Date:  2014-04-15

7.  Recent advances in biomarkers and potential targeted therapies in head and neck squamous cell carcinoma.

Authors:  Eric J Yavrouian; Uttam K Sinha
Journal:  ISRN Surg       Date:  2012-02-15

8.  Investigation of the expression of the EphB4 receptor tyrosine kinase in prostate carcinoma.

Authors:  Yen-Ching Lee; Janeanne R Perren; Evelyn L Douglas; Michael P Raynor; Maria A Bartley; Peter G Bardy; Sally-Anne Stephenson
Journal:  BMC Cancer       Date:  2005-09-20       Impact factor: 4.430

9.  Coexpression of EphB4 and ephrinB2 in tumour advancement of ovarian cancers.

Authors:  S M Alam; J Fujimoto; I Jahan; E Sato; T Tamaya
Journal:  Br J Cancer       Date:  2008-01-29       Impact factor: 7.640

10.  Ephrin-B2 reverse signaling regulates progression and lymph node metastasis of oral squamous cell carcinoma.

Authors:  Eri Sasabe; Ayumi Tomomura; Riki Tomita; Shinya Sento; Naoya Kitamura; Tetsuya Yamamoto
Journal:  PLoS One       Date:  2017-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.